Advertisement

Zusammenfassung

In den letzten Jahren kam vorübergehend die Hoffnung auf, dem Ziel der Frühdiagnostik kolorektaler Karzinome näherzukommen. Unter Frühdiagnostik sei die zuverlässige Diagnostik von Dukes-A- bzw. T1/T2-N0-M0-Tumoren verstanden (Hermanek et al. 1987).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Atkinson BF, Ernst CS. Herlyn M. Steplewski Z, Sears HF, Koprowski H (1982) Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 42:4820–4823PubMedGoogle Scholar
  2. Bast RC, Klug TL, John ES et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 309:883–887PubMedCrossRefGoogle Scholar
  3. Baum RP, Maul FD, Klapdor R et al. (1985) Immunszintigraphie colorektaler Tumoren mit J-l31-markierten monoklonalen Antikörpern (19-9/anti-CEA) — Erste Ergebnisse. Nuc Compact 16:121–128Google Scholar
  4. Bodansky O (1954) Serum phosphoterose isomerase in cancer as an nides of tumor growth in metastatic carcinoma of the breast. Cancer J: 1200–1226Google Scholar
  5. Chatal JF, Saccavini JC, Fumoleau P et al. (1984) Immunoscintigraphy of colon carcinoma. J Niicl Med 25:307–314Google Scholar
  6. Colcher D, Horan Hand P, Nuti P, Schlom JA (1981) Spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:3199–3203PubMedCrossRefGoogle Scholar
  7. Del Villano BC, Brennan S, Brock P et al. (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29:549–552PubMedGoogle Scholar
  8. Dallek M, van Ackeren H, Klapdor R, Klapdor U, Bahlo M, Greten H, Saeger W (1985) Primary diagnosis and follow-up of colorectal and stomach cancer with the tumour associated antigens CEA, CA 19-9 and CA 125. In:Greten H, Klapdor R (eds) New tumour associated antigens — two years clinical experience with monoclonal antibodies — 2nd Symposium on Tumour Markers, Hamburg 1984. Thieme, Stuttgart New York, pp 35–42Google Scholar
  9. Dietel M. Arps H, Klapdor R, Müller-Hagen S, Sieck M, Hoffmann L (1986) Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients’ sera. J Cancer Res Clin Oncol 111:257–265PubMedCrossRefGoogle Scholar
  10. Fossel ET. Carr JM, McDonagh J (1986) Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 315:1369–1376PubMedCrossRefGoogle Scholar
  11. Genollá J, Mane S, Moragas G, Colomer R, Rosell M, Ruibal A (1987) Usefulness of CA50 serum levels in clinical practice. In:Klapdor R (ed) New tumour markers and their monoclonal antibodies — Actual clinical relevance for diagnosis and therapy of solid tumours; 4th Symposium on Tumor Markers, Hamburg 1986. Thieme, Stuttgart New York, pp 184–187Google Scholar
  12. Gronowitz JS, Källander CFR, Hagberg H, Diderholm H, Petterson U (1984) Application of an in vitro assay for serum thymidine kinase:results on viral disease and malignancies in humans. Int J Cancer 33:5–11PubMedCrossRefGoogle Scholar
  13. Haglund C. Kuusela P, Jalanko H, Roberts PJ (1987) Serum CA 50 as a tumor marker in pancreatic cancer:a comparison with CA 19-9. Int J Cancer 39:477–481PubMedCrossRefGoogle Scholar
  14. Helfrich G. Klapdor U, Bahlo M, Klapdor R. Schreiber HW (1987) Determination of the tumor markers CA 19-9. CA 125, CA 15-3, CA 50 and CEA in acute and chronic benign diseases in medical/surgical patients. In:Klapdor R (ed) New tumor markers and their monoclonal antibodies — actual clinical relevance for diagnosis and therapy of solid tumours; 4th Symposium on Tumor Markers, Hamburg 1986. Thieme, Stuttgart New York, pp 287–290Google Scholar
  15. Hermanek P, Scheibe O, Spiessl B, Wagner G (eds) (1987) TNM-Klassifikation maligner Tumoren, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  16. Holmgren J, Lindholm L, Persson B et al. (1984) Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J 288:1479–1482CrossRefGoogle Scholar
  17. Holstege A, Pauff M, Kirchner R, Gerok W (1987) Increased urinary excretion of modified nucleosides in cases of colorectal carcinoma:comparison with CEA and correlation to tumor progression. In:Klapdor R (ed) New tumor markers and their monoclonal antibodies — actual clinical relevance for diagnosis and therapy of solid tumors; 4th Symposium on Tumor Markers, Hamburg 1986. Thieme, Stuttgart New York, pp 265–269Google Scholar
  18. Heptner G, Domschke S, Krapf F, Schneider MU, Iro H, Domschke W (1984) Vergleich der Tumormarker CEA and CA 19-9 in der kolorektalen Diagnostik. Dtsch Med Wochenschr 109:1309–1312PubMedCrossRefGoogle Scholar
  19. Jalanko H, Haglund C, Roberts PJ, Kuusela P (1985) Tumor markers in gastrointestinal cancers. In:Homgren J (ed) Tumor marker antigens — Properties and usefulness of carcinoma associated antigens CEA, CA 19-9 and CA 50. Chartwell-Bratt, Bromley, pp 114–122Google Scholar
  20. Katsuyuki N, Kathuhisa S, Yasaka T (1985) Reversed-phase high-performanee liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. J Chromatography 343:21–33CrossRefGoogle Scholar
  21. Klapdor R (1988) Colonkarzinom-Früherkennung 1987. Z Gastroenterol 23:45–50Google Scholar
  22. Klapdor R (1988) Stellenwert der Tumormarker bei der Früherkennung gastrointestinaler Tumoren. Verh. Dtsch Ges. Innere Med 94:29–40Google Scholar
  23. Klapdor R, Greten H (1984) Das tumorassoziierte Antigen CA 19-9 in der Differentialdiagnostik und Verlaufskontrolle von Malignomen des Pankreas und Magen-Darm-Traktes. Dtsch Med Wochenschr 109:1935–1937PubMedCrossRefGoogle Scholar
  24. Klapdor R, Lehmann U, Bahlo M, Greten H, van Ackeren H, Dallek M, Schreiber HW (1983) CA 19-9 in der Diagnostik und Differentialdiagnostik des exkretorischen Pankreaskarzinoms. Tumor Diagn Ther 4:197–201Google Scholar
  25. Klapdor R, Klapdor U, Bahlo M et al. (1984) CA 125 bei Karzinomen des Verdauungstraktes — Ein Vergleich mit CA 19-9 und CEA bei Karzinomen des Pankreas und Colon. Dtsch Med Wochenschr 109:1949–1952PubMedCrossRefGoogle Scholar
  26. Klapdor R, Klapdor U, Montz R, Dietel M, Arps H, Schreiber HW, Greten H (1987) New tumor associated antigens and their monoclonal antibodies in the follow-up of exocrine pancreatic carcinoma. In:Klapdor R (ed) New tumor markers and their relevance for diagnosis and therapy of solid tumors. 4th Symposium on Tumor Markers, Hamburg 1986. Thieme, Stuttgart New York, pp 154–166Google Scholar
  27. Klapdor R, Harms F, Bahlo M, Arps H, Dietel M (1989) Tumor marker secretion (CA 19-9, CEA, CA 125) by xenografts of 8 different human pancreatic carcinomas compared to the human tumors. Strahlentherapie (im Druck)Google Scholar
  28. Klapdor U, Bahlo M, Strüven D, Klapdor R (1988) Bedeutung der Thymidin-Kinase (TK) für die Diagnostik und Verlaufskontrolle gastrointestinaler Karzinome. Z Gastroenterologie 26:611 (Abstrakt)Google Scholar
  29. Kleist S von (1983) Das karzinoembryonale Antigen (CEA). Schattauer, Stuttgart New YorkGoogle Scholar
  30. Kleist S von (1988) What’s new in tumor markers and their measurements? Path Res Pract 183:95–99CrossRefGoogle Scholar
  31. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  32. Koprowski H, Steplewski Z, Mitchell K, et al. (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–972PubMedCrossRefGoogle Scholar
  33. Martin EW, Copperman M, Carey LC, Minton JB (1980) Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Drug Res 28:389–394Google Scholar
  34. Mentges B, Brückner R (1986) Das Kolonkarzinom:prognostische Faktoren. Dtsch Med Wochenschr 111:1790–1794PubMedCrossRefGoogle Scholar
  35. Merangos PJ, Zis AP, Clark RL, Goodwin FK (1987) Neurosal, non-neurosal and hybrid forms of enolase in brain:structural, immunological and function componsons. Brain Res 150:117–121CrossRefGoogle Scholar
  36. Montz R, Klapdor R, Rothe B, Heller M (1986) Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma. Nucl Med 25:239–244Google Scholar
  37. Nakano K, Shindo K, Yasaka T (1985) Reversed-phase high-performance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. J Chromatogr 343:21–33PubMedCrossRefGoogle Scholar
  38. Quentmeier A, Möller P, Schwarz V, Abel U, Schlag P (1987) Carcinoembryonic antigen, CA 19-9, and CA 125 in normal and carcinomatous human colorectal tissue. Cancer 60:2261–2266PubMedCrossRefGoogle Scholar
  39. Singe CC, Ewe K (1985) Kolorektale Präkanzerosen. Dtsch Med Wochenschr 110:1043–1046PubMedCrossRefGoogle Scholar
  40. Staab HJ (1984) Medizinisch-biologische Bedeutung des Carcino-embryonalen Antigens (CEA):Klinische Studien und experimentelle Modelle. Editiones Roche, BaselGoogle Scholar
  41. Staab HJ, Glocks S, Hornung A (1982) Ein neuer Festphasen-Enzymimmunotest mit monoklonalem Antikörper zur CEA Bestimmung bei Patienten mit verschiedenen Karzinomen. Tumor Diagn Ther 4 /5:183–194Google Scholar
  42. Vierbuchen M, Imdahl A, Uhlenbruck G, Fischer R (1986) Immunohistochemische Untersuchungen über das Vorkommen und die Natur der tumorassoziierten Antigene CA 50 und CA 19-9 in normaler und neoplastischer Dickdarmschleimhaut. Labor-Medizin 9:544–550Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • R. Klapdor

There are no affiliations available

Personalised recommendations